
DeviceTalks Podcast Network
476 episodes — Page 9 of 10

Can Drawbridge, Edwards bring disruptive innovation to blood drawing, heart surgery industries?
In this week’s podcast, we talk with Holly Logue, general counsel at Drawbridge Health, about the OneDraw, an innovative new tool that might upend the collecting, storage and testing of blood. Logue, a panelist in the upcoming DeviceTalks Tuesdays sponsored by Finnegan, will explain how her past work on Capitol Hill is helping this Silicon Valley company’s plans. Meanwhile, we speak with Daveen Chopra, corporate vice president of surgical structural heart at Edwards Lifesciences, about that company’s commitment to treating the most serious cardiac patients. The company recently won FDA approval for its Konect Resilia aortic valve conduit, a vital new tool in helping heart patients, including many requiring emergency story. Co-costs Tom Salemi, editorial director of DeviceTalks, and Chris Newmarker, executive editor of life sciences at MassDevice, review the five biggest news stories of the week. We'll talk about Abbott, Becton Dickinson, Boston Scientific, Edwards Lifesciences, and Theranos. Number one may surprise you.

Is Medtech finally ready to capitalize on the promise of connectivity?
For years, medtech companies have known connectivity was good for them, but the promise of data streaming through devices didn't match the reality. COVID-19 changed that, creating an opportunity for device companies with connectivity plans in place. In this episode, we speak with Dr. David Hayes, CMO of Biotronik, about that companies success in connecting cardiology patients. Meanwhile, Bill Betten of S3 Connected Health explains what device companies must do to prepare for medtech's next age. We also review the week's top news involving Medtronic, Johnson & Johnson, Abbott, Edwards, and Smith+Nephew

CVRx Nadim Yared on COVID-19, diversity and equality; Hyalex CEO Mira Sahney shares startup details
DeviceTalks Weekly: Ep. 17 – In this week’s episode of DeviceTalks Weekly, we follow up with Nadim Yared, CEO of CVRx, the guest of last week’s episode, to catch up on how the medtech executives is managing during the pandemic. Yared also shares some far-reaching views on what the medtech industry needs to work toward to improve diversity in its workforce and provide equality for society. We also visit with Mira Sahney, CEO of Hyalex Orthopaedics, one of medtech’s most interesting startups; Hyalex was identified as a notable startup in the recent report in Medical Design and Outsourcing. In this interview, Sahney reveals Hyalex’ origins, the state of its potential cartilage replacement product, and why start-ups have a natural advantage operating in a pandemic. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

CVRx CEO Nadim Yared on his path from engineer to CEO to industry leader.
Nadim Yared, CEO of CVRx This week, CVRX reported positive six-month trial results for its Barostim Neo, an FDA-approved treatment for heart failure. The results follow years of close work between the agency and CVRx, one of the more ambitious startups in medtech. CVRx is targeting a huge clinical need with novel neuromodulation technology. In this week’s DeviceTalks Weekly podcast, CEO Nadim Yared walks us through the negotiations the company went through with the FDA to get to this point. Yared, the prior chairman of the industry group AdvaMed, also shares the story of his career, which started early on when he secured a job at GE even before graduating college. In this talk, Yared speaks to several issues including: The power of confidence and the dangers of overconfidence when building a career. -How he decided to take the job at CVRx (and why he didn’t initially want to talk about the job with a recruiter.) -What CVRx learned from other successes and failures in renal denervation. -Why the company is betting big on heart failure, but doesn't have a Chief Medical Officer. -Whether or not his role as chairman at AdvaMed impacted his work at CVRx. -Can medtechs generate good returns after raising hundreds of millions in capital? This conversation took place prior to the emergence of COVID-19, so DTW host Tom Salemi visited again with Yared more recently. We’ll play that interview in next week’s episode of DeviceTalks Weekly. If you’re looking for more medtech discussions, register now for DeviceTalks Weekly at devicetalks.com. Subscribe to he podcast. Don’t miss an episode!

Why FDA put the pedal to the metal for radar and hummingbirds. And why medtech needs Google.
DeviceTalks Weekly: Ep. 15 – Why FDA put the pedal to the metal for radar and hummingbirds. And why medtech needs Google. In this week’s episode of DeviceTalks Weekly, co-hosts Chris Newmarker and Tom Salemi dig into the recent successes by start-ups Circadia Health and Perceptis Medical, which both saw expedited approval from the FDA due to the pandemic. We also unveil the 20 medical device companies you need to know. https://www.medicaldesignandoutsourcing.com/20-medical-device-startups-you-need-to-know-2020/ Circadia CEO Fares Siddiqui discusses the quick approval that came for his company’s C100 system that uses radar to monitor respiratory function. Preceptis Medical CEO Steve Anderson, meanwhile, explains why the agency – and he hopes payers – want to see his company’s ear-tube implanting system on the market. We also visit with Heidi Dohse, Sr. Program Manager at Google’s Cloud Healthcare & Life Sciences organization, who will be leading the upcoming DeviceTalks Tuesday’s discussion about how medtech devices can use data to better serve its sickest patients. https://www.devicetalks.com/devicetalks-tuesdays-agenda/ Dohse partners with physicians and researchers around the world to provide insights regarding the patient experience and ideas for engagement. She travels globally educating audiences on digital health, data and healthcare. On Tuesday, she’ll discuss. • How do we weigh “patient lifestyles” vs. “therapy/product” lifecycles”? • What impact will connected devices and apps have on patient outcomes? • How can data help improve and even transform the patient experience? • Speaker: Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

Stryker's Kevin Lobo, Dexcom's Kevin Sayer talk diversity, COVID-19; also more on Medtronic deal
This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company – and the industry group AdvaMed – has been working to increase diversity of its workforce, particularly in senior and sales positions. Lobo is serving a two-year term as chairman of AdvaMed. In this interview, Lobo speaks specifically to how Stryker is tracking progress, where it has come up short, and how it’s working to help workers identify their own biases. Lobo also says Stryker is poised to regain momentum after the pandemic. Next, Kevin Sayer, executive chairman, CEO and president of Dexcom, says the company’s continuous glucose monitors are finding a home in hospitals as they help monitor the health of COVID-19 patients. Sayer says the company’s monitors have helped keep patients, especially diabetics, off ventilators and allowed them to get discharged more quickly. What’s next for Dexcom? “We think this is an important market for us, not just COVID-wise,” Sayer says. Finally, Raj Denhoy, equity research analyst at Jefferies, breaks down private equity group Blackstone’s investment in Medtronic’s diabetes line. Why would the medtech giant take outside money? Is this something we’ll see more of in medtech? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup
DeviceTalks Weekly: Ep. 13 – Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup In this week’s episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health. Ryan came to Cala from the venerable medtech investor Johnson & Johnson Development Corp., where she made over 15 investments helping to create companies including Auris Surgical, Cala and digital surgery play Verb Surgical, J&J’s joint venture with Verily. “I really set my mind to [asking] was there a way we could create our own opportunities,” she said of her eight years as the corporate investor. We ask Ryan about her move into medtech investing from investment banking as well as the “secret power” that helped her succeed as an investor and an executive. We’ll also discuss the unique commercial strategy Cala is employing as it begins rolling out its Cala Trio, a bioelectronic device developed to treat essential tremor. The interview was conducted in February. What role will tech companies play in medtech’s future? Did Verb Surgical meet her expectations? As CEO how do you manage investor syndicates with multiple corporate investors? Can Cala secure reimbursement and create a new market for tremors? What grade did she skip as a child? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

DTW's Commencement Speaker- Todd Brinton, MD, Edwards Lifesciences on building a career in medtech
In this week’s DeviceTalks Weekly podcast, we attempt to deliver heartfelt and hard won advice in a sort of commencement address by Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer of Edwards Lifesciences. Dr. Brinton sits down with host Tom Salemi to share his path into Medtech. Brinton shares great advice for anyone looking for a new career or opportunity in medtech. NOTE: This conversation was recorded in March, prior to the full impact of the COVID-19 pandemic.

Medtronic is buckling up and ready to buy
DeviceTalks Weekly: Ep. 11 – Medtronic is buckling up and ready to buy In this week’s episode of DeviceTalks Weekly, we dip into Medtronic’s quarterly call to hear why company executives feel the medtech sector is already rebounding. The global giant also intends to start using its vast cash reserves to bolster its bottomline through M&A. We’ll also talk with Jeff Champagne of MPR about medtech’s need for speed. He’ll be leading a discussion on this subject and more on the upcoming DeviceTalks Tuesdays. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

How do medtech investors, CEOS manage portfolio companies going forward?
DeviceTalks Weekly: Ep. 10 – How do medtech investors, CEOS manage portfolio companies going forward? In this week’s episode of DeviceTalks Weekly, we talk with two successful starters of medtech companies about how they’re building and maintaining their medtech portfolios during this pandemic landscape. Our guests this week are… • Justin Klein, MD, managing partner, Vensana Capital • Duke Rohlen, chairman, Ajax Health Together, Klein and Rohlen have created, backed and sold medtech companies that have generated billions. Klein, formerly of New Enterprise Associates, now co-manages his own venture firm, Vensana Capital. He previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), EPIX Therapeutics (acquired), FIRE1, GPB Scientific, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical, and VytronUS (acquired). Rohlen, who leads a holdings company backed by private equity giant KKR, previously served as chairman and CEO of EPIX, Co-founder, Chairman and CEO of Spirox, Inc (sold to Entellus Medical) and co-founder and CEO of CV Ingenuity. He was also president of Fox Hollow before it was acquired by EV3. In this podcast we’ll learn how VCs are looking at investment opportunities in this market • Are they making new investments? • What impact is this having on valuation? • Do VCs give stronger consideration to new concerns like supply chain? • When will they get clinical trials up and running? Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

DeviceTalks Weekly: Ep. 9 – What’s the state of the Medtech job market?
In this week’s episode of DeviceTalks Weekly, Tom Salemi speaks with two executive recruiters about what they see in the medtech market. Over the past month, we’ve seen several medtech companies – big and small – cutting jobs and reducing hours but what does this mean long-term. In this podcast we’ll identify a few companies that are hiring, but we’ll talk in-depth with the recruiters about… • How bad is the current market? • What’s the likelihood for recovery? • What skills are in greater demand? • What can people do to strengthen their hand? Guests are: • David L. Vied, global sector leader, Global Sector Leader, Medical Devices and Diagnostics, Korn Ferry • Giovanni Lauricella, vice president, medtech practice-lead, The Mullings Group Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

AdvaMed‘s Scott Whitaker on pandemic readiness, Jon Norris of SVB shares Q1 VC data
DeviceTalks Weekly: Ep. 8 – AdvaMed‘s Scott Whitaker on pandemic readiness, Jon Norris of SVB shares Q1 venture capital investment data In this week’s episode of DeviceTalks Weekly, Scott Whitaker, CEO of AdvaMed, shares concerns he had over how the federal government would work with the medtech industry during the pandemic crisis. Does he feel the medtech industry was treated fairly? How does he see the federal government and medtech industry working together in the future? He answers those questions and more. In our second interview, Jonathan Norris, managing director of Silicon Valley Bank, shares first-quarter data for medtech venture investments. The results might surprise you. Guests are: • Scott Whitaker, CEO, AdvaMed • Jonathan Norris, managing director, Silicon Valley bank Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

DeviceTalks Weekly: Ep.7 – Edwards, Employment News, Update on Clinical Trials from Avania
In this week’s episode of DeviceTalks Weekly, Tom Salemi and Chris Newmarker stare at each other through the Zoom lens while talking about the positive news from Baxter and Conformis, the hopeful projections from Edwards, and the cautionary tone from Medtronic. We also interview Mark McIlduff, general manager, US, at the newly named CRO, Avania on the state of clinical trials. What changes might we expect in the future? Mark brings great insights. Guests are: • Mark McIlduff, general manager, US, Avania Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

DeviceTalks Weekly: Ep.6 – Hear about the Coventor, Q1 Earnings and MassDevice’s Medtech 100 Index
DeviceTalks Weekly: Ep.6 – Hear about the Coventor Ventilator, COVID-19 and Q1 Earnings and MassDevice’s Medtech 100 Index In this week’s episode of DeviceTalks Weekly, Aaron Tucker of the Earl Bakken Medical Center shares the origin of the recently approved Coventor ventilator, which will be manufactured at-cost by Boston Scientific. We’ll also hear Abbott CEO Robert Ford comments from the company’s Q1 analyst call as we begin to dissect how the COVID-19 pandemic will impact medtech earnings. Finally, Danielle Kirsh, senior editor at WTWH Media, will share the origins of our new Medtech 100 Index, a powerful new tool for measuring how large medtech companies are managing in this new economy. Guests are: • Aaron Tucker, Lab Supervisor, University of Minnesota Earl E. Bakken Medical Device Center • Danielle Kirsh, Senior Editor, WTWH Media Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

DeviceTalks Weekly: Ep.5 –What impact is COVID-19 having on start-ups?
DeviceTalks Weekly: Ep.5 –What impact is COVID-19 having on start-ups? Raising capital for start-up is never easy. Try doing it during a pandemic. In this week’s DeviceTalks Weekly, we’ll try to help entrepreneurs by talking with two guests who are committed to helping start-ups find the funding they need. Paul Grand, founder and CEO of MedTech Innovator, explains how he’s working to keep start-ups connected to capital. His popular MedTech Innovator program is adapting to the times and creating new ways for start-ups to get in front of investors. We’ll also talk with Shai Policker, CEO at MEDX Xcelerator, an incubator backed by Boston Scientific, Intellectual Ventures and others. Based in Israel, MEDX is moving forward and interested in investing capital in start-ups worldwide. Co-host Chris Newmarker, executive editor, life sciences, for WTWH Media, also updates us on what articles are drawing the most interest on MassDevice and Medical Design and Outsourcing. Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

DeviceTalks DeviceTalks Weekly: Ep.4 –What does Medtronic's Puritan reveal mean for medtech?
DeviceTalks Weekly: Ep.4 –What does Medtronic's Puritan reveal mean for medtech? Medtronic’s earned plaudits and praise for sharing the design specifications for its Puritan Bennett 560 (PB560) ventilators. But will the gesture actually lead to more ventilators being manufactured? In this episode of DeviceTalks Weekly, we’ll talk with experts who will tell us what the plans do and do not say. We’ll also get some legal insights on what strings are attached to the open source effort. Guests are: • D. Brian Kacedon, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP • Lee Teschler, Executive Editor, WTWH Media • Scott Thielman, CTO, Product Creation Studio Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.

DeviceTalks Weekly ep. 3 - Making Sense of Medtech's Regulatory Alphabet Soup
In this week’s DeviceTalks Weekly, we’ll examine how governmental effort, both foreign and domestic, are hitting the medtech industry. Our guests include Tracy Eberly, CEO of Fang Consulting, a regulatory advisory group. Eberly will update listeners on what pushing back the MDR deadline could mean for medtech companies and why some companies may be less than thrilled with the decision. In our second conversation, Joy Sturm, procurement expert and partner at the DC office of Law Firm Hogan Lovells, walks us through the powers contained within the Defense Production Act invoked last week by the Trump administration. Sturm, who brings 20-years of governmental purchasing experience to the conversation, answer several key questions including: What CAN and CAN’T the government do under the act? Which federal agencies are responsible for executing the DPA? Can companies secure capital to pay for DPA-supported efforts? What player is missing on the field in the battle against COVID-19? Also, AdvaMed is also looking for direction from the Federal government. You may be surprised by the potential source of leadership. Finally, MassDevice Honcho Chris Newmarker talks DYI ventilators. Check out Mass Device's Sean Whooley's feature here. And what does the FDA say about these projects?

DeviceTalks Weekly, Ep. 2 - Medtech goes to War
In this week’s DeviceTalks Weekly Podcast, hosts Tom Salemi and Chris Newmarker will detail medtech’s essential role in the escalating war against COVID-19. This week’s guests are Fluidda CEO Jan De Backer and Kevin Thornal, division president of diagnostic solutions at Hologic. The executive will explain how their new FDA tools will aid against the diagnosis and treatment of COVID-19. We also ask them how the recently invoked Defense Production Act will impact medtech’s fight against the pandemic.

DeviceTalks Weekly, Episode 1, - Raj Denhoy, Jefferies
Welcome to the DeviceTalks Weekly Podcast, a regular – and sometimes irregular – opportunity to visit with the editorial team at MassDevice and Medical Design and Outsourcing. This week, Chris Newmarker, Executive Editor, Life Sciences, at WTWH Media, reviews our COVID-19 coverage with Tom Salemi, Editorial Director, DeviceTalks. Tom also chats with Raj Denhoy, Managing Director, Equity Research Analyst at Jefferies, who details how the Medtech sector is fairing in this unprecedented uncertainty. While most Medtechs stand on strong financial footing, Denhoy issues a warning to investors that another correction may be coming once analysts start assessing the impact on earnings. Still, he says there are safe havens out there and identifies one in the podcast. Finally, Tom and Chris explore what impact social distancing may have on medtech in the short-term – sales and deals - and long-term – innovation.

Intuitive Surgical CEO Gary Guthart plans to stay on top
Gary Guthart, the longtime CEO of Intuitive Surgical, tells MassDevice.com Executive Editor Brad Perriello why he's so confident about staying on top of the robot-assisted surgery heap, the company's five buckets for in-house R&D; and what he looks for in potential business partners.

Inside Google and Johnson & Johnson's bid to change surgery
DeviceTalks goes inside the union of two of the most innovative companies in the world, Google and Johnson and Johnson as they look to change the face of surgery. In this episode, we chat with Scott Huennekens, President and CEO, Verb Surgical, the robotic surgery platform spinout from Google and JNJ. Huennekens shares with us the mission of Verb, insights from his career in medical startups and why he thinks robots will be performing surgery in 50 years.

DeviceTalks Live: Being a woman in the corner office of medtech
There's an old saying that Ginger Rogers did everything Fred Astaire did but she did it backwards and in high heels. For Nancy Briefs, Deborah DiSanzo and Martha Shadan, it's also a challenge they know well. These CEOs and medtech veterans have made the journey from the ranks of the medtech industry to the corner office, making them, sadly, a rarity in this industry where just 1 out of 7 women in medicine hold senior executive positions. In this panel, recorded live at our DeviceTalks Boston event features remarks from DiSanzo, IBM Watson General Manager, Ms. Briefs, CEO, InfoBionic and Ms. Shadan, CEO, Rotation Medical.

The evolution of OCTANe and Orange County's technology ecosystem
Bill Carpou took over at OCTANe 18 months ago with the mission to increase Orange County, California's image as a technology super hub. Through programs like the Medical Device Investor Forum and a new emphasis on helping local companies stay in the area, OCTANe is one of the most innovative industry council's in the medical device space. We talked to Bill about OCTANe's upcoming event, as well as its recent merger with the Orange County Technology Alliance.

Changing the face of dialysis with NxStage Medical founder Jeff Burbank
Jeff Burbank started NxStage Medical in 1999 on the premise that patients with chronic kidney disease would benefit from bringing hemodialysis out of the clinic and into their homes. Now, 17 years later Burbank's hypothesis has been proven out and his Lawrence, Mass.-based company is topping more than $300 million in annual sales, while making a real difference in the lives of patients. In this interview, recorded at DeviceTalks Boston on September 28, 2016, we sit down with Jeff to discuss his business journey.

Does culture eat strategy for breakfast? A chat with Smiths Medical CEO Jeff McCaulley
When Jeffery McCaulley took the reigns at Smiths Medical, the company was in a slump. Several years of flat growth and a potential merger that didn’t go through, had sapped the winning spirit of the Twin Cities, Minn.- based company. However, with McCaulley’s arrival, came a renewed sense of what was possible for Smiths Medical. The medtech veteran employed several new initiatives, honed at companies like GE to rebuild the company’s culture and move it back on a path to growth. In this podcast, we discuss McCaulley’s playbook when it comes to fostering a winning culture in the medical device industry.

Teleflex CEO Benson Smith on what it takes to be great in sales
This interview, recorded live on June 6, 2016 in St. Paul, Minn. at DeviceTalks Minnesota, is one of the funniest, most enlightening and interesting discussions we've ever had at DeviceTalks. Teleflex CEO Benson Smith takes us through his career from door-to-door salesman to CEO of 1 of the top performing medical device companies in the past five years. Listen all the way to the end to hear an unforgettable tale of going all out to get the job.

Leading the battle against sepsis with Spectral Medical CEO Paul Walker
Dr. Paul Walker speaks to MassDevice about his efforts to take on endotoxins and sepsis at the head of Spectral Medical, his history with the deadly condition and what’s next for the burgeoning Canadian medical device firm.

How we built the company with Innovative Trauma Care's Joe Brennan
Innovative Trauma Care, a San Antonio, TX-based startup, has found a new way to stop the bleeding. The company's flagship product, the iTClamp is a hemorrhage control device for use in the extremities, scalp and neck. The device, which looks like a hair clip, seals the edges of a wound closed to stop further blood loss until the wound can be surgically repaired. We spoke to CEO Joe Brennan about the device and how it can help improve survival rates in trauma incidents.

Fighting the war on brain cancer with NovoCure chairman Bill Doyle
Novocure, the St. Helier, Jersey-based medical device company, which raised more than $158M in an IPO last year, is trying to change the way we fight cancer. Company officials say its proprietary tumor treating fields technology, marketed under the product name Optune, are a new tool in the war against some of the deadliest forms of cancer. MassDevice publisher Brian Johnson recently caught up with Doyle to discuss the technology, the company's origins and how its current concentration on glioblastoma is just the beginning.

How I built the company with Patrick Daly, CEO, Cohera Medical
Patrick Daly, CEO, Cohera Medical talks to MassDevice Executive Editor, Brad Perriello about starting up the absorbable surgical adhesives and sealants company, how he raised one of the largest seed rounds in history and why he's moving the company to Raleigh, NC. This episode was recorded on February 29, 2016 at DeviceTalks Raleigh.

What it's like to be the CEO of the world's largest medtech company with Bill Hawkins
On this episode of DeviceTalks we dive into life in the corner office with Bill Hawkins, former CEO of Medtronic and chairman of Immucor. Hawkins shares his experiences on the front lines of medicine where he has spent 25 years leading companies as diverse as start ups to the world's largest medical device company.

Talking innovation with Johnson & Johnson's medtech R&D guru Martin Fitchet
Martin Fitchet is responsible for R&D at JNJ's medical device unit, a tall task for anyone but appropriate for this former surgeon. In this episode of DeviceTalks, we talk about what innovation means to a behemoth like JNJ and what areas he sees in medicine that are ripe for disruption.

A medtech veteran takes on C.diff: Rebiotix CEO Lee Jones
Clostridium difficile or C. diff. is a growing crisis in the U.S. with over 29,000 deaths and 500,000 cases annually, according to the CDC. The disease, which CDC officials warned can kill people in less than 30 days, is characterized by severe diarrhea, fever, and loss of appetite. Sadly, many elderly and infirmed patients are among the most vulnerable. Roseville, Minn.-based Rebiotix is one of a handful of companies looking to harness the human microbiome into a treatment for recurrent C. diff, which impacts about 20-30% of patients, where there are currently no approved drugs to treat patients with two or more recurrences. Rebiotix is currently in Phase 2 clinical trials for the treatment, which harnesses gut microbiota and turns them into therapies. The company hopes recurrent C. diff is just the 1st in a pipeline of treatments than can be derived from the microbiome. On this episode of DeviceTalks we discuss C.diff with Reviotix CEO Lee Jones. What personal stories led her to this mission; How powerful the human microbiome will be in the future of combating disease and the differences between running a medtech company and a biotech company.

The leadership lessons of Stryker's John Brown
For a man who took a private company from $17 million in sales to a $4.5 billion publicly traded juggernaut, John Brown is a remarkably humble man. However, he is, by all intents and purposes, the man who put Stryker on the map. Today, the Kalamazoo, Mich.-based medical device company nets nearly $10 billion in annual sales. In this episode of DeviceTalks, recorded at the recent AdvaMed 2015 conference, Brown spoke to us about how he built such impressive results during his tenure at Stryker, including the lessons he learned along the way.

Can Sirtex turn cancer into a chronic disease?
Big things sometimes come in small packages. For Sirtex Medical, the big thing comes in a really small package. The Australian medical device company’s flagship product - the SIR-sphere - is made up of 30 to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and flow into the liver where they kill tumors from the inside. In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson talks with Mangano about the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech companies to enter.

Building the Cologuard and the fight against colorectal cancer with Exact Sciences Graham Lidgard
Colon cancer is one of the most preventable cancers, yet it is also one of the deadliest forms of the disease. In this episode, we speak with Graham Lidgard, the Chief Science Officer, Senior Vice President of Research and Development at Exact Sciences, a Wisc. -based company that has developed a non invasive test to detect colorectal cancer without having to undergo a colonoscopy. We talk to Graham about the Cologuard test and his 40 year career developing breakthrough medical technology.

Exit interview: Stephen Ubl moves on from AdvaMed
Before Stephen Ubl departed for a job as the chief lobbyist for the pharmaceutical industry, medtech's main man in Washington D.C. sat down with us to reflect on his time as CEO of AdvaMed. In this episode of DeviceTalks, we go deep into Ubl's background, the fights over the medical device tax, forging a new partnership with the FDA and more.

Marie Johnson and the mission to prevent sudden heart attacks
Marie Johnson turned tragedy into a mission. In 2002, the CEO of Aum Cardiovascular lost her husband to a sudden heart attack, despite the fact that he was, by all accounts, a perfectly healthy man. Fast forward 13 years and her company has commercialized a non-invasive test designed to quickly detect significant coronary stenosis called the CADence. Johnson hopes the pre FDA-approved device, which is on the market in Germany, will eliminate needless death due to coronary artery disease. In this interview, recorded live at our DeviceTalks Minnesota event, touches on Johnson's incredible story.

One of medtech's most successful men reflects on failure
Dr. Manny Villafana is one of the most successful men in the history of medical innovation, having founded four companies, including CPI/Guidant Corp. and St. Jude Medical, Inc. His most recent venture, Kips Bay Medical was supposed to be his best work yet. However, problems with the FDA and shortfalls on funding doomed the company, which shut down in September 2015. Recorded live on September 23rd at DeviceTalks Minnesota, just one day after he resigned as CEO of Kips Bay Medical, we discuss failure with Dr. Villafana. How does someone who has had so much success deal with the opposite? What comes next for this serial entrepreneur?

The story behind Airing: One of medtech's most successful crowdfunding campaign
Stephen Marsh has more than 70 patents to his name but his most recent endeavor, the Airing device, may make him a household name. The Airing is a hoseless, maskless, disposable micro CPAP machine, which could one day change the game in sleep apnea. However, Marsh and company have already made quite the mark on medtech by running one of the most successful crowdfunding campaigns ever. The company has raised more than $1 million on Indiegogo, more than 10 times its initial goal. In this episode of DeviceTalks, we talk to Marsh about the Airing device, inventing technology that sticks and how the company pulled off such a successful crowd funding campaign.

Spinal cord injuries and the quest to find a better treatment with Invivo Therapeutics Mark Perrin
Ten years after it was spun out of MIT, Invivo Thereapeutics and its neuro scaffold treatment for traumatic spinal cord injuries is moving closer to a reality. The company has completed enrollment of its 5 patient pilot study, which has made headlines around the world and is looking to push forward on adding more patients. In this episode of DeviceTalks, we talk to new CEO Mark Perrin about the company and why there has been so little movement in the fight against paralysis.

Behind the Boston Scientific turnaround with CEO Mike Mahoney
In this episode of DeviceTalks, recorded live at our DeviceTalks Boston event at Boston Scientific's corporate headquarters, we sit down with CEO Mike Mahoney to discuss the company's recent turnaround. Mahoney, who joined the company as its CEO in 2012, sat down with MassDevice's Brian Johnson to take us inside how the company has improved its performance.

Battling obesity with the alternative to bariatric surgery| ReShape Medical CEO Richard Thompson
Reshape Medical recently received FDA approval for its Duo balloon system for obesity. The company bills the device as an alternative to bariatric surgery for the majority of patients suffering from this global epidemic. In this episode we dig into the obesity epidemic and how ReShape Medical is looking to change the paradigm of care for patients needing to lose a significant amount of weight.

What makes Minnesota's medical alley tick with LifeScience Alley's Shaye Mandle
In this episode we catch up with LifeScience Alley CEO Shaye Mandle about doing business in Minnesota's world class medical device cluster. We delve into why the medical device and life sciences community clustered in the Twin Cities, what trends are developing in funding, m&a and technology in the area and, of course, where to go for a power breakfast in the area.

How teaching computers to recognize emotion led to healthcare innovation: MIT's Rosalind Picard
In this episode of DeviceTalks, we delve deeply into emotion and how teaching computers to recognize emotions led to a potentially major breakthrough in medical technology with MIT scientist and entrepreneur Rosalind Picard. Listen to hear the backstory behind her book Affective Computing, her work with artificial intelligence and pioneering wearable technology.

Changing the game with rotator cuff disease| A conversation with Martha Shadan
Rotation Medical is changing the game when it comes to treating rotator cuff disease, one of the most prevalent orthopedic conditions that people suffer from. We talk to CEO Martha Shadan about Rotation Medical's revolutionary biologic treatment and how the orthopedic world is changing.

Fighting depression with medical devices
Tal Medical's roots go back to a serendipitous discovery at McLean Hospital where patients suffering from bi-polar disorder reported feeling better after MRI. In this episode of DeviceTalks, Jan Skvarka, CEO, Tal Medical tells us about how that discovery could one day lead to a new clinical pathway for care for patients suffering from acute depression.

How I built the company with Merit Medical CEO Fred Lampropoulos | DeviceTalks
In this DeviceTalks podcast, we talk with Merit Medical founder and CEO Fred Lampropoulos about starting the Utah-based medical device company, his thoughts on leadership and his experience as a musician opening for The Doors and The Beach Boys.

How I built the company with Masimo CEO Joe Kiani
Medtech entrepreneur, patient safety advocate Joe Kiani, CEO, Masimo Corp. talks about building the company from scratch. In addition, he discusses his mission as the founder of the Patient Safety Movement Foundation, recorded at DeviceTalks West on November 19, 2014. Also featured, B. Braun CEO Carroll Neubauer.

Inside one of the largest medtech companies in the world| B. Braun Medical CEO Caroll Neubauer
MassDevice publisher Brian Johnson interviews Caroll Neubauer, CEO, B. Braun Medical about the medical device tax, Obamacare, patient safety and the current state of the medical device industry.